Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Non-Current Debt (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Non-Current Debt for 11 consecutive years, with $798000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt fell 79.29% to $798000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $798000.0, a 79.29% decrease, with the full-year FY2025 number at $798000.0, down 79.29% from a year prior.
  • Non-Current Debt was $798000.0 for Q4 2025 at Ekso Bionics Holdings, down from $1.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $5.1 million in Q3 2023 to a low of $798000.0 in Q4 2025.
  • A 5-year average of $3.1 million and a median of $3.3 million in 2025 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: skyrocketed 89.01% in 2022, then plummeted 79.29% in 2025.
  • Ekso Bionics Holdings' Non-Current Debt stood at $2.0 million in 2021, then surged by 89.01% to $3.8 million in 2022, then grew by 28.27% to $4.8 million in 2023, then decreased by 20.24% to $3.9 million in 2024, then tumbled by 79.29% to $798000.0 in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Non-Current Debt are $798000.0 (Q4 2025), $1.1 million (Q3 2025), and $3.3 million (Q2 2025).